Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics of 14C-labeled OP-724 in healthy male volunteers
jRCT2031230432Phase 1Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foscenvivint, sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetics of 14C-labeled OP-724. Started Nov 2023; status: completed.
02
Drugs
foscenvivint
Beyond the preview
Go deeper on jRCT2031230432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230432.